1.Masoud D, et al. Guidelines for control of tuberculosis in prisons. Tuberculosis Coalition for Technical Assistance and International Committee of the Red Cross, January 2009.
2.Bick JA. Infection control in jails and prisons. Clinical Infectious Disease 2007; 45: 1047–1055.
3.Kariminia A, et al. Factors associated with mortality in a cohort of Australian prisoners. European Journal of Epidemiology 2007; 22: 417–428.
4.Horsburgh CR Jr., Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. New England Journal of Medicine 2011; 364: 1441–1448.
5.Abebe DS, et al. Prevalence of pulmonary tuberculosis and associated risk factors in Eastern Ethiopian prisons. International Journal of Tuberculosis and Lung Disease 2011; 15: 668–673.
6.Stuckler D, et al. Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proceedings of the National Academy of Sciences USA 2008; 105: 13280–13285.
7.Lönnroth K, et al. Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet 2010; 375: 1814–1829.
8.Layton MC, et al. Universal radiographic screening for tuberculosis among inmates upon admission to jail. American Journal of Public Health 1997; 87: 1335–1337.
9.Kowada A. Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening. Molecular Diagnosis and Therapy 2012; 16: 181–190.
10.de Perio MA, et al. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Archives of Internal Medicine 2009; 169: 179–187.
11.Kowada A, et al. Cost-effectiveness analysis of interferon-γ release assays versus chest X-ray for annual tuberculosis screening of healthcare workers. Journal of Hospital Infection 2011; 78: 152–154.
12.Kowada A. Cost-effectiveness of interferon-γ release assay versus chest X-ray for tuberculosis screening of employees. American Journal of Infection Control 2011; 39: e67–72.
13.Kowada A. Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy. Molecular Diagnosis and Therapy 2010; 14: 367–373.
14.Hardy AB, et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010; 65: 178–180.
15.Hoffmann M, Ravn P. The use of interferon-gamma release assays in HIV-positive individuals. European Infectious Disease 2010; 4: 23–29
16.Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of Internal Medicine 2008; 149: 177–184
17.Tattevin P, et al. The validity of medical history, classic symptoms, and chest radiographs in predicting pulmonary tuberculosis: derivation of a pulmonary tuberculosis prediction model. Chest 1999; 115: 1248–1253.
18.Cohen R, et al. The validity of classic symptoms and chest radiographic configuration in predicting pulmonary tuberculosis. Chest 1996; 109: 420–423.
21.Yoshiyama T. Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings [in Japanese]. Kekkaku 2000; 75: 629–641.
22.Chee CB, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. European Respiratory Journal 2010; 36: 355–361.
23.Igakutsushin-sya. Medical insurance reimbursement table in Japan [in Japanese]. Igakutsushin-sya 2012.
25.Resch SC, et al. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Medicine 2006; 3: e241.
26.Marra CA, et al. Health-related quality of life trajectories among adults with tuberculosis: differences between latent and active infection. Chest 2008; 133: 396–403.
27.Baussano I, et al. Tuberculosis incidence in prisons: a systematic review. PLoS Medicine 2010; 7: e1000381.
28.Reichard AA, et al. Assessment of tuberculosis screening and management practices of large jail systems. Public Health Reports 2003; 118: 500–507.
29.Lee D, et al. Global fund financing of tuberculosis services delivery in prisons. Journal of Infectious Diseases 2012; 205: S274–283.
30.Reid SE, et al. Tuberculosis and HIV control in sub-Saharan African prisons: ‘thinking outside the prison cell’. Journal of Infectious Diseases 2012; 205: S265–273.
31.Puisis M, et al. Radiographic screening for tuberculosis in a large urban county jail. Public Health Reports 1996; 111: 330–334.
32.Leung CC, et al. Chest radiograph screening for tuberculosis in a Hong Kong prison. International Journal of Tuberculosis and Lung Disease 2005; 9: 627–632.
33.Jones TF, Schaffner W. Miniature chest radiograph screening for tuberculosis in jails: a cost-effectiveness analysis. American Journal of Respiratory and Critical Care Medicine 2001; 164: 77–81.
34.Chan PC, et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. International Journal of Tuberculosis and Lung Disease 2012; 16: 633–638.
35.Horsburgh CR Jr.. Priorities for the treatment of latent tuberculosis infection in the United States. New England Journal of Medicine 2004; 350: 2060–2067.
36.Tuberculosis Research Committee (Ryoken). Relapse rate of tuberculosis treated with standard regimen of chemotherapy [in Japanese]. Kekkaku 2009; 84: 617–625.
37.International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bulletin of the World Health Organization 1982; 60: 555–564.
38.Menzies D, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Annals of Internal Medicine 2008; 149: 689–697.
39.Takayama N, et al. Cumulative national immunization rate of BCG vaccine in Japan [in Japanese]. Japan Medical Association Journal 2009; 137: 2132–2136.